Publisher
Springer Science and Business Media LLC
Reference64 articles.
1. Schlaeppi, J. M., & Wood, J. M. (1999). Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors. Cancer and Metastasis Review, 18, 473–481.
2. Folkman, J. (2003). Angiogenesis inhibitors: a new class of drugs. Cancer Biology & Therapy, 2, S127–S133.
3. Abdollahi, A., & Folkman, J. (2010). Evading tumor evasion: Current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resistance Updates, 13, 16–28.
4. Korpanty, G., Smyth, E., & Carney, D. N. (2011). Update on anti-angiogenic therapy in non-small cell lung cancer: Are we making progress? Journal of Thoracic Disease, 3, 19–29.
5. Tozer, G. M., Kanthou, C., & Baguley, B. C. (2005). Disrupting tumour blood vessels. Nature Reviews. Cancer, 5, 423–435.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献